Bhimani, Jenna
Ball, Katie
Stebbing, Justin
Article History
Received: 11 October 2019
Revised: 29 October 2019
Accepted: 19 November 2019
First Online: 10 January 2020
Ethics approval and consent to participate
: Not applicable
: Not applicable.
: Not applicable.
: In 2018—present Professor Stebbing, the Editor-in-Chief of Oncogene sat on SABs for Celltrion, Singapore Biotech, Vor Biopharma, TLC Biopharmaceuticals and Benevolent AI, has consulted with Lansdowne partners, Vitruvian and Social Impact Capital and he chairs the Board of Directors for BB Biotech Healthcare Trust and Xerion Healthcare. Jenna Bhimani and Katie Ball declare no competing interests.
: This work is supported by the Imperial BRC and ECMC.
Free to read: This content has been made available to all.